

Philip H Elsinga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4007146/publications.pdf>

Version: 2024-02-01

177
papers

5,957
citations

66343

42
h-index

91884

69
g-index

185
all docs

185
docs citations

185
times ranked

6058
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Staging of Patients With Carcinoid and Islet Cell Tumors With ¹⁸ F-Dihydroxy-Phenyl-Alanine and ¹¹ C-5-Hydroxy-Tryptophan Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2008, 26, 1489-1495.	1.6	240
2	Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. <i>Lancet Oncology</i> , The, 2006, 7, 728-734.	10.7	234
3	Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. <i>Journal of Nuclear Medicine</i> , 2003, 44, 331-5.	5.0	201
4	Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. <i>Journal of Nuclear Medicine</i> , 2004, 45, 695-700.	5.0	189
5	PET Studies on P-Glycoprotein Function in the Blood-Brain Barrier: How it Affects Uptake and Binding of Drugs within the CNS. <i>Current Pharmaceutical Design</i> , 2004, 10, 1493-1503.	1.9	159
6	6-[F-18]Fluoro-L-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3922-3930.	3.6	153
7	Phosphoramidite accelerated copper(i)-catalyzed [3 + 2] cycloadditions of azides and alkynes. <i>Chemical Communications</i> , 2009, , 2139.	4.1	149
8	PET Tracers for Imaging of the Dopaminergic System. <i>Current Medicinal Chemistry</i> , 2006, 13, 2139-2153.	2.4	136
9	Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 199-213.	4.4	135
10	Potential applications for sigma receptor ligands in cancer diagnosis and therapy. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2015, 1848, 2703-2714.	2.6	127
11	Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1049-1062.	6.4	113
12	Strain-Promoted Copper-Free Click Chemistry for ¹⁸ F Radiolabeling of Bombesin. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 11117-11120.	13.8	113
13	Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. <i>Journal of Nuclear Medicine</i> , 2005, 46, 400-4.	5.0	108
14	Fully automated synthesis module for the high yield one-pot preparation of 6-[¹⁸ F]fluoro-L-DOPA. <i>Applied Radiation and Isotopes</i> , 1999, 51, 389-394.	1.5	106
15	VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment. <i>Cancer Research</i> , 2011, 71, 143-153.	0.9	105
16	Copper-free Click™: 1,3-dipolar cycloaddition of azides and alkynes. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 3461.	2.8	102
17	Sigma Receptors in Oncology: Therapeutic and Diagnostic Applications of Sigma Ligands. <i>Current Pharmaceutical Design</i> , 2010, 16, 3519-3537.	1.9	96
18	Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3-Deoxy-3-Deoxy-L-Thymidine. <i>Clinical Cancer Research</i> , 2004, 10, 1685-1690.	7.0	93

#	ARTICLE	IF	CITATIONS
19	Synthesis and Evaluation of (S)-4-(3-(2- ¹¹ C-isopropylamino)-2-hydroxypropoxy)-2H-benzimidazol-2-one ((S)-[¹¹ C]CGP 12388) and (S)-4-(3-(1- ¹⁸ F-fluoroisopropyl)amino)-2-hydroxypropoxy)-2H-benzimidazol-2-one ((S)-[¹⁸ F]Fluoro-CGP) <i>Tj ETQ</i> 1 1 0.784314 <i>rgB</i> <i>Chemistry, 1997, 40, 3829-3835.</i>		
20	The cholinergic system, sigma-1 receptors and cognition. <i>Behavioural Brain Research</i> , 2011, 221, 543-554.	2.2	78
21	18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2004, 45, 226-31.	5.0	70
22	Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. <i>Journal of Nuclear Medicine</i> , 2006, 47, 150-4.	5.0	70
23	Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5291.	4.1	66
24	Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT. <i>Current Pharmaceutical Design</i> , 2013, 19, 4647-4672.	1.9	65
25	Oxygen Activated, Palladium Nanoparticle Catalyzed, Ultrafast Cross-Coupling of Organolithium Reagents. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 3354-3359.	13.8	62
26	3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma?. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1927-32.	5.0	61
27	In Vivo Biodistribution of No-Carrier-Added 6-18F-Fluoro-3,4-Dihydroxy-L-Phenylalanine (18F-DOPA), Produced by a New Nucleophilic Substitution Approach, Compared with Carrier-Added 18F-DOPA, Prepared by Conventional Electrophilic Substitution. <i>Journal of Nuclear Medicine</i> , 2015, 56, 106-112.	5.0	60
28	Imaging the Folate Receptor on Cancer Cells with ^{99m} Tc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 701-704.	5.0	59
29	Radiopharmaceutical chemistry for positron emission tomography. <i>Methods</i> , 2002, 27, 208-217.	3.8	58
30	Proliferation Markers for the Differential Diagnosis of Tumor and Inflammation. <i>Current Pharmaceutical Design</i> , 2008, 14, 3326-3339.	1.9	58
31	Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 8.	3.9	58
32	EANM guideline on the validation of analytical methods for radiopharmaceuticals. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 7.	3.9	57
33	Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. <i>Psychopharmacology</i> , 2015, 232, 3443-3453.	3.1	55
34	Synthesis and evaluation of ¹¹ C- and ¹⁸ F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. <i>Nuclear Medicine and Biology</i> , 2003, 30, 273-284.	0.6	54
35	Manipulation of [¹¹ C]-5-Hydroxytryptophan and 6-[¹⁸ F]Fluoro-3,4-Dihydroxy-L-Phenylalanine Accumulation in Neuroendocrine Tumor Cells. <i>Cancer Research</i> , 2008, 68, 7183-7190.	0.9	54
36	Synthesis and Preclinical Evaluation of Novel PET Probes for P-Glycoprotein Function and Expression. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4524-4532.	6.4	52

#	ARTICLE	IF	CITATIONS
37	Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. <i>Journal of Nuclear Medicine</i> , 2002, 43, 167-72.	5.0	52
38	Carbon-11 labelled tyrosine to study tumor metabolism by positron emission tomography (PET). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1986, 12, 321-324.	2.1	50
39	Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain. <i>Molecular Imaging and Biology</i> , 2005, 7, 37-44.	2.6	48
40	An Update of Radiolabeled Bombesin Analogs for Gastrin-Releasing Peptide Receptor Targeting. <i>Current Pharmaceutical Design</i> , 2013, 19, 3329-3341.	1.9	48
41	Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1677-82.	5.0	45
42	Carbon-11 choline or FDG-PET for staging of oesophageal cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1845-1849.	6.4	44
43	Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 615-620.	1.0	44
44	Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography. <i>Journal of Controlled Release</i> , 2020, 324, 303-316.	9.9	41
45	Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: A continuous infusion PET study in conscious monkeys. <i>Synapse</i> , 2006, 59, 18-26.	1.2	40
46	Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1939-45.	5.0	37
47	Quantitative imaging of 5-HT1A receptor binding in healthy volunteers with [18f]p-MPPF. <i>Nuclear Medicine and Biology</i> , 2000, 27, 473-476.	0.6	35
48	Potential Therapeutic Applications of Adenosine A _{2A} Receptor Ligands and Opportunities for A _{2A} Receptor Imaging. <i>Medicinal Research Reviews</i> , 2018, 38, 5-56.	10.5	35
49	PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?. <i>Current Pharmaceutical Design</i> , 2004, 10, 1519-1536.	1.9	35
50	Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 135-154.	3.0	34
51	18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. <i>Journal of Nuclear Medicine</i> , 2007, 48, 367-72.	5.0	34
52	Feasibility of [18F]-RGD for ex vivo imaging of atherosclerosis in detection of $\alpha_5\beta_1$ integrin expression. <i>Journal of Nuclear Cardiology</i> , 2015, 22, 1179-1186.	2.1	32
53	Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1355-1360.	5.0	32
54	^{99m} Tc-Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(¹⁴ C) as a Targeted Imaging Agent with MicroSPECT in a PC-3 Prostate Cancer Xenograft Model. <i>Molecular Pharmaceutics</i> , 2011, 8, 1165-1173.	4.6	31

#	ARTICLE	IF	CITATIONS
55	Development of [¹⁸ F]-Labeled Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH442416) Analogs for the Imaging of Cerebral Adenosine A _{2A} Receptors with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6765-6780.	6.4	30
56	Avenues to molecular imaging of dying cells: Focus on cancer. <i>Medicinal Research Reviews</i> , 2018, 38, 1713-1768.	10.5	30
57	Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 768-773.	2.8	30
58	Synthesis and Preclinical Evaluation of 2-(2-Furanyl)-7-[2-[4-[4-(2-[¹¹ C]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine ([¹¹ C]Preladenant) as a PET Tracer for the Imaging of Cerebral Adenosine A _{2A} Receptors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9204-9210.	6.4	29
59	Evaluation of [¹⁸ F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1286-1298.	4.3	29
60	(S,S)- and (S,R)-1- ¹⁸ F-fluorocarazolol, ligands for the visualization of pulmonary β_2 -adrenergic receptors with PET. <i>Nuclear Medicine and Biology</i> , 1996, 23, 159-167.	0.6	28
61	Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals. <i>Nuclear Medicine Communications</i> , 2015, 36, 414-422.	1.1	28
62	Synthesis and preliminary evaluation of (R,S)-1-[2-((Carbamoyl-4-hydroxy)phenoxy)-ethylamino]-3-[4-(1-[¹¹ C]-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol ([¹¹ C]CGP 20712A) as a selective β_1 -adrenoceptor ligand for PET. <i>Nuclear Medicine and Biology</i> , 1994, 21, 211-217.	0.6	27
63	Evaluation of [¹¹ C]SA5845 and [¹¹ C]SA4503 for imaging of sigma receptors in tumors by animal PET. <i>Annals of Nuclear Medicine</i> , 2005, 19, 701-709.	2.2	27
64	Synthesis and Evaluation of [¹⁸ F]-FEAnGA as a PET Tracer for β_2 -Glucuronidase Activity. <i>Bioconjugate Chemistry</i> , 2010, 21, 911-920.	3.6	27
65	Effect of radiotherapy and chemotherapy on bone marrow activity. <i>Nuclear Medicine Communications</i> , 2011, 32, 17-22.	1.1	27
66	Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with ¹¹ C-SA4503 and microPET. <i>Psychopharmacology</i> , 2014, 231, 3997-4006.	3.1	27
67	Evaluation of cardiac beta-adrenoreceptors in the isolated perfused rat heart using (S)- ¹¹ C-CGP12388. <i>Journal of Nuclear Medicine</i> , 2004, 45, 471-7.	5.0	27
68	¹⁸ F-FEAnGA for PET of β_2 -Glucuronidase Activity in Neuroinflammation. <i>Journal of Nuclear Medicine</i> , 2012, 53, 451-458.	5.0	26
69	EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 34.	3.9	26
70	Cytotoxicity of β_2 -Receptor Ligands Is Associated with Major Changes of Cellular Metabolism and Complete Occupancy of the β_2 -Subpopulation. <i>Journal of Nuclear Medicine</i> , 2008, 49, 2049-2056.	5.0	24
71	Small-Animal PET Study of Adenosine A ₁ Receptors in Rat Brain: Blocking Receptors and Raising Extracellular Adenosine. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1293-1300.	5.0	24
72	Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer. <i>Amino Acids</i> , 2013, 44, 543-553.	2.7	24

#	ARTICLE	IF	CITATIONS
73	PET Tracers for Imaging of ABC Transporters at the Blood-Brain Barrier: Principles and Strategies. <i>Current Pharmaceutical Design</i> , 2016, 22, 5779-5785.	1.9	24
74	Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier. <i>Molecular Pharmaceutics</i> , 2015, 12, 2265-2275.	4.6	23
75	Initial Evaluation of an Adenosine A _{2A} Receptor Ligand, ¹¹ C-Preladenant, in Healthy Human Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1464-1470.	5.0	23
76	Synthesis and evaluation of ¹⁸ F-fluorometoprolol as a potential tracer for the visualization of β -adrenoceptors with PET. <i>Nuclear Medicine and Biology</i> , 1993, 20, 637-642.	0.6	22
77	Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging. <i>Medicinal Research Reviews</i> , 2019, 39, 1014-1052.	10.5	22
78	Ultrafast Photoclick Reaction for Selective ¹⁸ F-Positron Emission Tomography Tracer Synthesis in Flow. <i>Journal of the American Chemical Society</i> , 2021, 143, 10041-10047.	13.7	22
79	Carbon-11 Labeled Tracers for In Vivo Imaging of P-Glycoprotein Function: Kinetics, Advantages and Disadvantages. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 1820-1833.	2.1	21
80	P-glycoprotein Function in the Rodent Brain Displays a Daily Rhythm, a Quantitative In Vivo PET Study. <i>AAPS Journal</i> , 2016, 18, 1524-1531.	4.4	21
81	Production of α -glucosidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 79-91.	4.0	21
82	Evaluation of fluorine-18-labeled alkylating agents as potential synthons for the labeling of oligonucleotides. <i>Applied Radiation and Isotopes</i> , 2003, 58, 469-476.	1.5	20
83	Synthesis and evaluation of a fluorine-18 labeled antisense oligonucleotide as a potential PET tracer for iNOS mRNA expression. <i>Nuclear Medicine and Biology</i> , 2004, 31, 605-612.	0.6	20
84	Rapid Reduction of α 1-Receptor Binding and ¹⁸ F-FDG Uptake in Rat Gliomas After In Vivo Treatment with Doxorubicin. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1320-1326.	5.0	20
85	Application of ^{99m} Tc-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients. <i>Nuclear Medicine and Biology</i> , 2013, 40, 933-938.	0.6	20
86	[¹⁸ F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer. <i>Movement Disorders</i> , 2019, 34, 924-926.	3.9	20
87	Synthesis and evaluation of dopamine D3 receptor antagonist ¹¹ C-GR218231 as PET tracer for P-glycoprotein. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1384-92.	5.0	20
88	Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1538-45.	5.0	20
89	Receptor imaging in the thorax with PET. <i>European Journal of Pharmacology</i> , 2004, 499, 1-13.	3.5	19
90	Evaluation of ⁴ [Methyl- ¹¹ C]Thiothymidine in a Rodent Tumor and Inflammation Model. <i>Journal of Nuclear Medicine</i> , 2012, 53, 488-494.	5.0	19

#	ARTICLE	IF	CITATIONS
91	In vivo evaluation of [¹¹ C]preladenant positron emission tomography for quantification of adenosine A _{2A} receptors in the rat brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 577-589.	4.3	19
92	In Vivo Evaluation of ¹¹ C-Preladenant for PET Imaging of Adenosine A _{2A} Receptors in the Conscious Monkey. <i>Journal of Nuclear Medicine</i> , 2017, 58, 762-767.	5.0	19
93	In vitro imaging of bacteria using 18F-fluorodeoxyglucose micro positron emission tomography. <i>Scientific Reports</i> , 2017, 7, 4973.	3.3	19
94	Despite irreversible binding, PET tracer [¹¹ C]-SA5845 is suitable for imaging of drug competition at sigma receptors – The cases of ketamine and haloperidol. <i>Neurochemistry International</i> , 2008, 53, 45-50.	3.8	18
95	Preclinical Evaluation and Quantification of 18F-Fluoroethyl and 18F-Fluoropropyl Analogs of SCH442416 as Radioligands for PET Imaging of the Adenosine A _{2A} Receptor in Rat Brain. <i>Journal of Nuclear Medicine</i> , 2017, 58, 466-472.	5.0	18
96	Visualization of ¹²⁵ I-Adrenoceptors Using PET. <i>Molecular Imaging and Biology</i> , 1998, 1, 81-94.	0.3	17
97	Positron Emission Tomography Studies of Human Airways Using an Inhaled ¹²⁵ I-Adrenoceptor Antagonist, S-11 C-CGP 12388. <i>Chest</i> , 2005, 128, 3020-3027.	0.8	17
98	A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [18F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 192-202.	3.0	17
99	MCR Scaffolds Get Hotter with 18F-Labeling. <i>Molecules</i> , 2019, 24, 1327.	3.8	17
100	Allosteric Interactions between Adenosine A _{2A} and Dopamine D ₂ Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1719.	4.1	17
101	Use of ¹¹ C-MPDX and PET to Study Adenosine A ₁ Receptor Occupancy by Nonradioactive Agonists and Antagonists. <i>Journal of Nuclear Medicine</i> , 2014, 55, 315-320.	5.0	16
102	Synthesis of [18F]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin $\alpha_5\beta_1$ expression in vivo. <i>Nuclear Medicine and Biology</i> , 2013, 40, 710-716.	0.6	15
103	Radiation Dosimetry of a Novel Adenosine A _{2A} Receptor Radioligand [¹¹ C]Preladenant Based on PET/CT Imaging and Ex Vivo Biodistribution in Rats. <i>Molecular Imaging and Biology</i> , 2017, 19, 289-297.	2.6	15
104	Late-Stage Copper-Catalyzed Radiofluorination of an Arylboronic Ester Derivative of Atorvastatin. <i>Molecules</i> , 2019, 24, 4210.	3.8	15
105	Multimerization Improves Targeting of Peptide Radio-Pharmaceuticals. <i>Current Pharmaceutical Design</i> , 2012, 18, 2501-2516.	1.9	15
106	Induction of ¹²⁵ I-Glucuronidase Release by Cytostatic Agents in Small Tumors. <i>Molecular Pharmaceutics</i> , 2012, 9, 3277-3285.	4.6	14
107	Small-Animal PET with a ¹²⁵ I-Ligand, ¹¹ C-SA4503, Detects Spontaneous Pituitary Tumors in Aged Rats. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1377-1383.	5.0	14
108	Application of Click Chemistry for PET. <i>Current Organic Chemistry</i> , 2013, 17, 2108-2118.	1.6	14

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetic Modeling of [18F]MC225 for Quantification of the P-Glycoprotein Function at the Blood-Brain Barrier in Non-Human Primates with PET. <i>Molecular Pharmaceutics</i> , 2020, 17, 3477-3486.	4.6	14
110	Multivalent Probes in Molecular Imaging: Reality or Future?. <i>Trends in Molecular Medicine</i> , 2021, 27, 379-393.	6.7	14
111	Modular Medical Imaging Agents Based on Azide-Alkyne Huisgen Cycloadditions: Synthesis and Pre-Clinical Evaluation of ¹⁸ F-Labeled PSMA-Tracers for Prostate Cancer Imaging. <i>Chemistry - A European Journal</i> , 2020, 26, 10871-10881.	3.3	13
112	Synthesis and Characterization of a Novel Series of Agonist Compounds as Potential Radiopharmaceuticals for Imaging Dopamine D _{2/3} Receptors in Their High-Affinity State. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 391-410.	6.4	12
113	Synthesis of ⁶ Li- ¹⁸ F-Fluoroprogesterone: A first step towards a potential receptor-ligand for PET. <i>Applied Radiation and Isotopes</i> , 1994, 45, 811-813.	1.5	11
114	Sigma-1 Agonist Binding in the Aging Rat Brain: a MicroPET Study with [11C]SA4503. <i>Molecular Imaging and Biology</i> , 2016, 18, 588-597.	2.6	11
115	<i>In Vivo</i> Induction of P-Glycoprotein Function can be Measured with [¹⁸ F]MC225 and PET. <i>Molecular Pharmaceutics</i> , 2021, 18, 3073-3085.	4.6	11
116	Small Molecule PET-Radiopharmaceuticals. <i>Current Pharmaceutical Design</i> , 2014, 20, 2268-2274.	1.9	11
117	New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging). <i>Current Pharmaceutical Design</i> , 2018, 24, 1287-1303.	1.9	11
118	EANM guideline on quality risk management for radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3353-3364.	6.4	11
119	Potential PET tracers for imaging of tumor-associated macrophages. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2022, 7, 11.	3.9	11
120	Asymmetric Synthesis of Carbon-11 Labelled α -Amino Acids for PET. <i>Current Organic Chemistry</i> , 2013, 17, 2127-2137.	1.6	10
121	Robotic synthesis of L-[1- ¹¹ C]tyrosine. <i>Applied Radiation and Isotopes</i> , 1994, 45, 821-828.	1.5	9
122	In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O- ¹²⁵ I-D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging ¹²⁵ I-Glucuronidase Activity in a Tumor/Inflammation Rodent Model. <i>Molecular Imaging</i> , 2012, 11, 7290.2011.00029.	1.4	9
123	Tailored imaging of islet cell tumors of the pancreas amidst increasing options. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 213-226.	4.4	9
124	Cerebral adenosine A1 receptors are upregulated in rodent encephalitis. <i>NeuroImage</i> , 2014, 92, 83-89.	4.2	9
125	The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented?. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 2.	3.9	9
126	Synthesis and biodistribution of [11C]procaterol, a ¹²⁵ I-adrenoceptor agonist for positron emission tomography. <i>Applied Radiation and Isotopes</i> , 2000, 52, 857-863.	1.5	8

#	ARTICLE	IF	CITATIONS
127	Synthesis and preliminary evaluation of (S)-[11C]-exaprolol, a novel $\hat{1}^2$ -adrenoceptor ligand for PET. <i>Neurochemistry International</i> , 2008, 52, 729-733.	3.8	8
128	Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1925-1936.	3.5	8
129	Test-Retest Repeatability of [18F]MC225-PET in Rodents: A Tracer for Imaging of P-gp Function. <i>ACS Chemical Neuroscience</i> , 2020, 11, 648-658.	3.5	8
130	[¹⁸ F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats. <i>Molecular Pharmaceutics</i> , 2021, 18, 3378-3386.	4.6	8
131	Synthesis of [11C]methyl magnesium iodide and its application to the introduction of [11C]-N-tert-butyl groups and [11C]-sec-alcohols. <i>Applied Radiation and Isotopes</i> , 1995, 46, 227-231.	1.5	7
132	Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology. <i>Current Pharmaceutical Design</i> , 2008, 14, 3340-3347.	1.9	7
133	In vivo evaluation of [18F]FEAnGA-Me: a PET tracer for imaging $\hat{1}^2$ -glucuronidase ($\hat{1}^2$ -GLUS) activity in a tumor/inflammation rodent model. <i>Nuclear Medicine and Biology</i> , 2012, 39, 854-863.	0.6	7
134	In Vivo Responses of Human A375M Melanoma to a $\hat{1}^f$ Ligand: 18F-FDG PET Imaging. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1613-1620.	5.0	7
135	Novel Approach to Repeated Arterial Blood Sampling in Small Animal PET: Application in a Test-Retest Study with the Adenosine A1 Receptor Ligand [11C]MPDX. <i>Molecular Imaging and Biology</i> , 2016, 18, 715-723.	2.6	7
136	Improving metabolic stability of fluorine-18 labeled verapamil analogs. <i>Nuclear Medicine and Biology</i> , 2018, 64-65, 47-56.	0.6	7
137	Evaluation of P-glycoprotein function at the blood-brain barrier using [18F]MC225-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4105-4106.	6.4	7
138	Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112260.	5.6	7
139	Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with $^{16}\hat{1}^2$ -18F-Fluoro-5 $\hat{1}^{\pm}$ -Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1140-1145.	5.0	7
140	Dose-response assessment of cerebral P-glycoprotein inhibition in vivo with [18F]MC225 and PET. <i>Journal of Controlled Release</i> , 2022, 347, 500-507.	9.9	7
141	Synthesis and Evaluation in Rats of the Dopamine D2/3 Receptor Agonist 18F-AMC20 as a Potential Radioligand for PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 133-139.	5.0	6
142	¹¹ C- and ¹⁸ F-Labeled Radioligands for P-Glycoprotein Imaging by Positron Emission Tomography. <i>ChemMedChem</i> , 2016, 11, 108-118.	3.2	6
143	Synthesis of Substituted Benzaldehydes via a Two-Step, One-Pot Reduction/Cross-Coupling Procedure. <i>Organic Letters</i> , 2019, 21, 4087-4091.	4.6	6
144	Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4307-4317.	6.4	6

#	ARTICLE	IF	CITATIONS
145	Trends on the Role of PET in Drug Development. , 2012, , .		6
146	MicroPET Evaluation of a Hydroxamate-Based MMP Inhibitor, [18F]FB-ML5, in a Mouse Model of Cigarette Smoke-Induced Acute Airway Inflammation. <i>Molecular Imaging and Biology</i> , 2015, 17, 680-687.	2.6	5
147	Correspondence re: H. Barthel et al., 3'-deoxy-3'-[(18F)fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. <i>Cancer Res.</i> , 63: 3791-3798, 2003. <i>Cancer Research</i> , 2003, 63, 8558-9; author reply 8560.	0.9	5
148	Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. <i>Cancers</i> , 2022, 14, 1924.	3.7	5
149	Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors. <i>EJNMMI Research</i> , 2014, 4, 53.	2.5	4
150	Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [18F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide. ⁴ <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 277-292.	3.0	4
151	Nomenclature for radiopharmaceuticals, consultation of your opinion!. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 2, 1.	3.9	4
152	Comparison of In Vitro Assays in Selecting Radiotracers for In Vivo P-Glycoprotein PET Imaging. <i>Pharmaceuticals</i> , 2017, 10, 76.	3.8	4
153	<i>In vitro</i> studies on CNGRC-CPG2 fusion proteins for ligand-directed enzyme prodrug therapy for targeted cancer therapy. <i>Oncotarget</i> , 2020, 11, 619-633.	1.8	4
154	cerebral beta-adrenoceptors. <i>Nuclear Medicine and Biology</i> , 2014, 41, 203-209.	0.6	3
155	[18F]Atorvastatin: synthesis of a potential molecular imaging tool for the assessment of statin-related mechanisms of action. <i>EJNMMI Research</i> , 2020, 10, 34.	2.5	3
156	Synthesis and Evaluation of [18F]FETLos and [18F]AMBF3Los as Novel 18F-Labelled Losartan Derivatives for Molecular Imaging of Angiotensin II Type 1 Receptors. <i>Molecules</i> , 2020, 25, 1872.	3.8	3
157	Mapping Arginase Expression with ¹⁸ F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary Î±-Amino Acids. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1163-1170.	5.0	3
158	Pharmacokinetic Modeling of (<i>R</i>)-[¹¹ C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates. <i>Molecular Pharmaceutics</i> , 2021, 18, 416-428.	4.6	3
159	PET Imaging of Adenosine A₁ Receptor Occupancy. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1918-1918.	5.0	2
160	Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1399-1399.	6.4	2
161	Spotlight on: guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals published in <i>EJNMMI Radiopharmacy and Chemistry</i> (2021)6:8. <i>Clinical and Translational Imaging</i> , 2021, 9, 281-282.	2.1	2
162	GMP Compliant Synthesis of [¹⁸ F]Canagliflozin, a Novel PET Tracer for the Sodiumâ€“Glucose Cotransporter 2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 16641-16649.	6.4	2

#	ARTICLE	IF	CITATIONS
163	Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January–June 2020). EJNMMI Radiopharmacy and Chemistry, 2021, 6, 5.	3.9	1
164	Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 13.	3.9	1
165	Production of Long-Acting CNGRC–CPC2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment. Technology in Cancer Research and Treatment, 2021, 20, 153303382110573.	1.9	1
166	Pharmacokinetic Modeling of [¹¹ C]GSK-189254, PET Tracer Targeting H ₃ Receptors, in Rat Brain. Molecular Pharmaceutics, 2022, 19, 918-928.	4.6	1
167	A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET. EJNMMI Radiopharmacy and Chemistry, 2022, 7, 3.	3.9	1
168	Obituary Nuclear Medicine and Biology - Volume 36, Issue 2. Nuclear Medicine and Biology, 2009, 36, 233-234.	0.6	0
169	Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D _{2/3} Receptors. International Journal of Molecular Imaging, 2014, 2014, 1-10.	1.3	0
170	Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. EJNMMI Physics, 2019, 6, 6.	2.7	0
171	Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 8.	3.9	0
172	Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. EJNMMI Research, 2019, 9, 34.	2.5	0
173	Endorsement of International Consensus Radiochemistry Nomenclature Guidelines. European Journal of Hybrid Imaging, 2019, 3, 6.	1.5	0
174	A new approach to produce [18F]MC225 via one-step synthesis, a PET radiotracer for measuring P-gp function. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 24.	3.9	0
175	The effects of molar activity on [18F]FDOPA uptake in patients with neuroendocrine tumors. EJNMMI Research, 2021, 11, 88.	2.5	0
176	Test–retest reproducibility of cerebral adenosine A _{2A} receptor quantification using [11C]preladenant. Annals of Nuclear Medicine, 2022, 36, 15-23.	2.2	0
177	Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D ₂ and Histamine H ₃ Receptors: A PET Study in Healthy Rats. Molecular Pharmaceutics, 0, , .	4.6	0